BioNumerik Pharmaceuticals, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Antonio TX United States (1992)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2001
NCT00039780
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma of Lung (Phase 3)

Brain Neoplasms (Phase 2)

Breast Diseases (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 3)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neurotoxicity Syndromes (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7